 The FDA has signed off Bio-Path Holdings Incs NASDAQ: BPTH Investigational New Drug IND application for BP1002 in refractoryrelapsed acute myeloid leukemia AML patients. In Phase 1 1b trial, six evaluable patients will be treated with BP1002 monotherapy in a standard 33 design, with a starting dose of 20 mgm2. 